Evolving Paradigms in Squamous NSCLC: Conclusion

At a median follow-up of 4.1 months, the overall response rate across all patients with advanced solid tumors treated with BL-B01D1 was 45.3%, according to data from a phase 1 study.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

The phase 3 LUNAR trial evaluating tumor treating fields with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer.

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.

New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.